Jan 18 (Reuters) - Erytech Pharma SA :
* Reported on Tuesday findings from preclinical studies demonstrate that ERY-MET, which is methionine gamma-lyase-encapsulated in red blood cells (RBC) developed using co’s proprietary ERYCAPS encapsulation platform technology, can inhibit tumor growth in a murine model of human gastric adenocarcinoma; this effect can be regulated by Vitamin B6 supplementation
* Methionine gamma-lyase-encapsulated into red blood cells (ERY-MET) shows profound antitumor activity in gastric carcinoma
* Study found that ERY-MET, in combination with daily Vitamin B6 supplementation, increased active MGL half-life in vivo, from less than 24 hours to 8-9 days.
* Combined ERY-MET and Vitamin B6 treatment exhibited anti-tumor activity in 100 pct of treated mice, with tumor growth inhibitions varying from 91 pct to 100 pct by the end of the study
Source text for Eikon: Further company coverage: